Orphazyme A/S

Orphazyme A/S (ORPH) priced its initial public offering on Sep 29, 2020 at $11.00 per ADS, raising $83.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $381.3M. BofA Securities was lead-left underwriter, joined by TD Cowen and Guggenheim. Cooley advised the company and A&O Shearman advised the underwriters.

Orphazyme A/S is a late-stage biopharmaceutical company developing therapeutics for neurodegenerative orphan diseases by amplifying Heat Shock Proteins. Its candidate arimoclomol has an FDA-accepted new drug application under priority review for Niemann-Pick disease Type C, and an EMA marketing authorization application is planned.

Status

IPO

Ticker

ORPH

Exchange

Nasdaq Global Select

Priced

Sep 29, 2020

IPO price

$11.00 per ADS

Raised

$83.8M

Market cap at IPO price

$381.3M

First filed

Sep 4, 2020

Underwriters

BofA Securities, TD Cowen and Guggenheim

Company counsel

Cooley

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

Denmark

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.